GENITOURINARY CANCERS

Daniel P. Petrylak, MD, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC).

Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Translational and Outcomes Research, Section of Urology, University of Chicago, discusses the adoption of robot-assisted surgery and its impact on treatment patterns for newly diagnosed localized prostate cancer patients.

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index and prostate cancer risk.

Peter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.

Stacy Loeb, MD, MSc, assistant professor, Department of Urology, Population Health, New York University, at the 2014 AUA Annual Meeting, discusses how urologists can use Twitter.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.

A rising prostate-specific antigen (PSA) after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy (ADT), a large observational study has found.

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the treatment of CRPC.

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

The combination of custirsen (OGX-011) with docetaxel and prednisone failed to significantly extend survival as a first-line treatment for men with mCRPC.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

Increasing efficacy with cancer vaccines, oncolytic viruses, and checkpoint inhibitors in clinical trials led to immunotherapy, as a whole, being deemed Breakthrough of the Year by Science magazine in 2013.

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer.

Robert Dreicer, MD, MS, Cleveland Clinic Lerner College of Medicine, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses PSA testing guidelines.

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses how his laboratory is working to improve the efficacy of abiraterone for the treatment of prostate cancer.